These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 2204244)

  • 1. New approach to develop a vaccine design against shigellosis.
    Sinha AK; Pal SC
    Vaccine; 1990 Aug; 8(4):410. PubMed ID: 2204244
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of vaccine and drug targets in Shigella dysenteriae sd197 using reverse vaccinology approach.
    Jalal K; Abu-Izneid T; Khan K; Abbas M; Hayat A; Bawazeer S; Uddin R
    Sci Rep; 2022 Jan; 12(1):251. PubMed ID: 34997046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shigellosis control--a rosy future?
    Kevsch GT
    J Infect Dis; 1977 Sep; 136(3):456-7. PubMed ID: 333037
    [No Abstract]   [Full Text] [Related]  

  • 4. Protection against shigellosis caused by Shigella dysenteriae serotype 4 in guinea pigs using Escherichia albertii DM104 as a live vaccine candidate strain.
    Chowdhury FM; Rahman MZ; Sarkar MMH; Rabbi F; Khan SI; Ahsan CR; Birkeland NK
    Acta Microbiol Immunol Hung; 2017 Jun; 64(2):151-164. PubMed ID: 28597684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shigellosis: the current status of vaccine development.
    Kweon MN
    Curr Opin Infect Dis; 2008 Jun; 21(3):313-8. PubMed ID: 18448978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of vaccines against shigellosis: memorandum from a WHO meeting.
    Bull World Health Organ; 1987; 65(1):17-25. PubMed ID: 3495364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivated and subunit vaccines to prevent shigellosis.
    Kaminski RW; Oaks EV
    Expert Rev Vaccines; 2009 Dec; 8(12):1693-704. PubMed ID: 19943764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An environmental Escherichia albertii strain, DM104, induces protective immunity to Shigella dysenteriae in guinea pig eye model.
    Chowdhury FM; Rahman MZ; Khan SI; Ahsan CR; Birkeland NK
    Curr Microbiol; 2014 May; 68(5):642-7. PubMed ID: 24452425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Genetic principles of activity and stability of attenuated live dysentery vaccines].
    Stenzel W
    Arzneimittelforschung; 1970 Oct; 20(10):1504-7. PubMed ID: 4921170
    [No Abstract]   [Full Text] [Related]  

  • 10. Towards a vaccine candidate against Shigella dysenteriae 1: expression of the Shiga toxin B-subunit in an attenuated Shigella flexneri aroD carrier strain.
    Tzschaschel BD; Klee SR; de Lorenzo V; Timmis KN; Guzmán CA
    Microb Pathog; 1996 Oct; 21(4):277-88. PubMed ID: 8905616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Core-linked LPS expression of Shigella dysenteriae serotype 1 O-antigen in live Salmonella Typhi vaccine vector Ty21a: preclinical evidence of immunogenicity and protection.
    Xu DQ; Cisar JO; Osorio M; Wai TT; Kopecko DJ
    Vaccine; 2007 Aug; 25(33):6167-75. PubMed ID: 17629369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Live attenuated Shigella flexneri mutants as vaccine candidates against shigellosis and vectors for antigen delivery.
    Phalipon A; Sansonetti P
    Biologicals; 1995 Jun; 23(2):125-34. PubMed ID: 7546655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of antibiotics in control of carriage of Shigella dysenteriae].
    VOROB'EVA NN; LESHCHINSKII IaL
    Pediatriia; 1956; 39(6):60-2. PubMed ID: 13408069
    [No Abstract]   [Full Text] [Related]  

  • 14. Epidemic shigellosis due to Shigella dysenteriae type 1 in south Asia.
    Pal SC; Sengupta PG; Sen D; Bhattacharya SK; Deb BC
    Indian J Med Res; 1989 Mar; 89():57-64. PubMed ID: 2661420
    [No Abstract]   [Full Text] [Related]  

  • 15. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults.
    Cohen D; Ashkenazi S; Green MS; Gdalevich M; Robin G; Slepon R; Yavzori M; Orr N; Block C; Ashkenazi I; Shemer J; Taylor DN; Hale TL; Sadoff JC; Pavliakova D; Schneerson R; Robbins JB
    Lancet; 1997 Jan; 349(9046):155-9. PubMed ID: 9111538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral vaccination against shigellosis by means of heat killed bacteria.
    Raettig H; Mamsch R
    Arch Immunol Ther Exp (Warsz); 1968; 16(2):324-32. PubMed ID: 5664132
    [No Abstract]   [Full Text] [Related]  

  • 17. Multi-serotype outer membrane vesicles of Shigellae confer passive protection to the neonatal mice against shigellosis.
    Mitra S; Chakrabarti MK; Koley H
    Vaccine; 2013 Jun; 31(31):3163-73. PubMed ID: 23684822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shigellosis.
    Niyogi SK
    J Microbiol; 2005 Apr; 43(2):133-43. PubMed ID: 15880088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oral immunization with bacterial microorganisms].
    Stanic M; Ungar J
    Ann Sclavo; 1972; 14(5):535-46. PubMed ID: 4592222
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunoprophylaxis against bacillary dysentery by dysentery live vaccine Vadizen (Shigella flexneri T32-Istrati) in children collectivities in SV County.
    Bogus L; Ianopol L; Dascălu C; Bende B; Iliescu C; Carliuc V; Meitert T; Pencu E; Ciudin L; Tonciu M
    Arch Roum Pathol Exp Microbiol; 1984; 43(3-4):291-8. PubMed ID: 6400302
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.